ADNI is one of the largest partnerships between the public and private sector focused on Alzheimer’s disease research. The initiative has sought to identify biological markers of potential Alzheimer’s risk in the blood, cerebrospinal fluid and DNA. Identifying these biomarkers also enhances scientific understanding of the genetic influences behind the disorder and chemical changes related to the disease. ADNI3 will add brain scans designed to detect tau protein tangles, which are a known indicator of Alzheimer’s.
“ADNI3 will move the bar higher still in this collaborative effort to gain a clear understanding of the subtle Alzheimer’s-related brain changes in volunteers, long before symptoms appear, and the biological changes that mark its progression,” said Richard J. Hodes, MD, director of the NIH’s National Institute of Aging. “These insights are vital to researchers and clinicians working worldwide in their selection of clinical trial volunteers and the testing of promising interventions.”
More articles on quality:
NPSF Lucian Leape Institute brings on noted patient advocate Sue Sheridan
Nursing home faces possible shutdown for failing to feed residents
NIH offers scientific symposium on the future of nursing science
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.